Abiopharma

Driven Brands Holdings Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and 39% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

BellRing Brands, Inc. Securities Fraud Class Action Result of Inventory Issues and 52% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Apollo Global Management, Inc. Securities Fraud Class Action Result of Undisclosed Relationship with Jeffrey Epstein and 16% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

SFHG attributes changed: Attr: Fin_status D -> N;

PTLE attributes changed: Attr: Fin_status D -> N;

JFBR attributes changed: Attr: Fin_status D -> N;

IVDA attributes changed: Attr: Fin_status N -> D;

RUBINSTEIN JULIE 🟡 adjusted position in 179.7K shares (3 derivative) of Adaptive Biotechnologies Corp (ADPT) at $14.08 ($3.0M) Transaction Date: Mar 11, 2026 | Filing ID: 000008

CarMax Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CarMax, Inc. - KMX

INVESTOR DEADLINE: Trip.com Group Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Director GRIFFIN MICHELLE RENEE 🔴 sold 15.4K shares of Adaptive Biotechnologies Corp (ADPT) at $13.91 Transaction Date: Mar 11, 2026 | Filing ID: 000006

LO FRANCIS 🔴 sold 30.6K shares of Adaptive Biotechnologies Corp (ADPT) at $14.08 Transaction Date: Mar 11, 2026 | Filing ID: 000011

BOBULSKY SUSAN 🔴 sold 41.3K shares of Adaptive Biotechnologies Corp (ADPT) at $13.17 Transaction Date: Mar 11, 2026 | Filing ID: 000004

Willard Stephen H 🟡 adjusted position in 494.5K shares (1 derivative) of Longeveron Inc. (LGVN) at $0.55 Transaction Date: Mar 02, 2026 | Filing ID: 003290